Masakazu Haneda

TL;DR: These findings provide the first in vivo evidence that the long‐term inhibition of PKC activation in the renal glomeruli can ameliorate glomerular pathologies in diabetic state, and suggest that a PKC β inhibitor might be an useful therapeutic strategy for the treatment of diabetic nephropathy.

TL;DR: Findings highlight the important role of PKC-MAPK pathway activation in mediating the development and progression of diabetic nephropathy.

TL;DR: Evidence is provided that mitogen-activated protein kinase (MAPK) cascade, an important kinase cascade downstream to PKC and an activator of cytosolic phospholipase A2 by direct phosphorylation, is activated in glomeruli isolated from streptozotocin-induced diabetic rats.

TL;DR: Although conventional therapeutic drugs like aldose reductase (AR) inhibitors and vasodilators have been shown to enhance nerve regeneration, their efficacy should be strictly evaluated with respect to nerve regenerative capacity.

TL;DR: The results indicated that immature intestinal stem cells can differentiate into insulin-producing cells given the ability to express the transcription factors Pdx-1 and Isl-1.